{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000400","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.331836+00:00","generated_at":"2026-06-18T09:52:39.342404+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Scholar Rock reports FY2022 net loss of $134.5M; revenue up to $33.2M; apitegromab Phase 3 enrollment on track for 2023","bullets":["Net loss of $134.5M ($2.26 per share) in FY2022; revenue $33.2M vs $18.8M prior year.","Cash, cash equivalents, and marketable securities of $315M; expects to fund ops into 2025.","Phase 3 SAPPHIRE trial enrollment of apitegromab on track to complete in 2023; top-line data expected 2024.","36-month extension data from Phase 2 TOPAZ trial expected in mid-2023; ~90% of patients remained on study.","Appointed Tracey M. Sacco as Chief Commercial Officer in Feb 2023 to lead launch preparation for apitegromab."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000400","json":"https://secwatch.observer/filing/0001157523-23-000400.json","markdown":"https://secwatch.observer/filing/0001157523-23-000400.md","text":"https://secwatch.observer/filing/0001157523-23-000400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/0001157523-23-000400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/a53357191.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:52:39.342404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a6d30cee05dd20ad65cb21ef0531dc31859798a","claim":"Scholar Rock Holding Corp reported the full year ended December 31, 2022 results: revenue $33.2 million, net income net loss was $134.5 million, EPS $2.26 per share.","evidence_excerpt":"For the full year ended December 31, 2022, net loss was $134.5 million or $2.26 per share compared to a net loss of $131.8 million or $3.59 per share for the full year ended December 31, 2021. Revenue was $33.2 million for the year ended December 31, 2022, compared to $18.8 million for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323000400/0001157523-23-000400-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$33.2 million"},{"label":"Net income","value":"net loss was $134.5 million"},{"label":"EPS","value":"$2.26 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}